alnylam pharmaceuticals inc  alnylam promotes akshay vaishnaw to senior vice president clinical research alnylam about alnylam about rnai delivery of rnai therapeutics scientific leadership strategic alliances intellectual property alnylam × ttr amyloidosis fap ttr amyloidosis fac hemophilia complementmediated disease porphyria cardiometabolic disease alpha antitrypsin deficiency hepatitis b virus infection betathalassemia and iron overload disorders other pipeline programs our story our culture careers management board of directors scientific advisory board               share this on delicious digg facebook linkedin twitter what is this alnylam promotes akshay vaishnaw to senior vice president clinical research  cambridge massbusiness wirejan  alnylam pharmaceuticals inc nasdaq alny a leading rnai therapeutics company today announced that it has promoted akshay vaishnaw md phd to the role of senior vice president clinical research in this role dr vaishnaw will be responsible for continued leadership of the companys clinical activities he will continue to report to john maraganore alnylams chief executive officer over the past few years akshay has demonstrated tremendous leadership in his role at alnylam and has been instrumental in the advancement of our pipeline said john maraganore phd chief executive officer of alnylam these are exciting times for the field of rnai therapeutics as important scientific and clinical advancements are being made at a very rapid pace with the continued development of our respiratory syncytial virus rsv infection program initiation of our phase i study for the treatment of liver cancers and an additional program expected to enter the clinic later this year akshays commitment to building a sustainable product pipeline of innovative medicines based on rnai has been an invaluable asset to the company we look forward to his continued leadership it is such an exciting time to be working in the field of rnai therapeutics i am very proud of the progress we have made in translating the science of rnai into the significant pipeline of development programs we have at alnylam today said dr vaishnaw i am fortunate for the outstanding team we have in place who are unwavering in their commitment to develop novel medicines for important diseases such as rsv infection and liver cancer amongst many others the coming year promises to be an important one for the company and for continued clinical development of rnai therapeutics dr vaishnaw joined alnylam in february  as vice president clinical research at alnylam he has played a significant role in the preclinical and clinical advancement of the companys pipeline of rnai therapeutics including alnrsv for the treatment of rsv infection and alnvsp for the treatment of liver cancers as well as other programs in the areas of hypercholesterolemia huntingtons disease and transthyretin ttr amyloidosis dr vaishnaw has also served as a member of alnylams management team prior to alnylam akshay served as senior director translational medicine at biogen idec in the seven years he was there he was involved in many aspects of clinical research and business development and led the effort for the approval of alefacept amevivetm for psoriasis dr vaishnaws other responsibilities at biogen idec included initiating a crossorganizational effort in translational medicine across all phases of development and multiple therapeutic areas participating on steering committees for external collaborations and in ma activity dr vaishnaw received his md from the university of wales college of medicine uk with distinctions in pathology and medicine and his phd from the university of london uk in molecular immunology he is a member of the royal college of physicians uk and received an executive mba from harvard business school in addition dr vaishnaw has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease about rna interference rnai rnai rna interference is a revolution in biology representing a breakthrough in understanding how genes are turned on and off in cells and a completely new approach to drug discovery and development its discovery has been heralded as a major scientific breakthrough that happens once every decade or so and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the  nobel prize for physiology or medicine rnai is a natural process of gene silencing that occurs in organisms ranging from plants to mammals by harnessing the natural biological process of rnai occurring in our cells the creation of a major new class of medicines known as rnai therapeutics is on the horizon rnai therapeutics target the cause of diseases by potently silencing specific messenger rnas mrnas thereby preventing diseasecausing proteins from being made rnai therapeutics have the potential to treat disease and help patients in a fundamentally new way about alnylam pharmaceuticals alnylam is a biopharmaceutical company developing novel therapeutics based on rna interference or rnai the company is applying its therapeutic expertise in rnai to address significant medical needs many of which cannot effectively be addressed with small molecules or antibodies the current major classes of drugs alnylam is leading the translation of rnai as a new class of innovative medicines with peerreviewed research efforts published in the worlds top scientific journals including nature nature medicine and cell the company is leveraging these capabilities to build a broad pipeline of rnai therapeutics its most advanced program is in phase ii human clinical trials for the treatment of respiratory syncytial virus rsv infection and is partnered with cubist and kyowa hakko in addition the company is developing rnai therapeutics for the treatment of a wide range of disease areas including liver cancers hypercholesterolemia huntingtons disease and ttr amyloidosis the companys leadership position in fundamental patents technology and knowhow relating to rnai has enabled it to form major alliances with leading companies including medtronic novartis biogen idec roche takeda kyowa hakko and cubist to reflect its outlook for key scientific clinical and business initiatives alnylam established rnai  in january  which includes the companys plan to significantly expand the scope of delivery solutions for rnai therapeutics have four or more programs in clinical development and to form four or more new major business collaborations all by the end of  alnylam is a joint owner of regulus therapeutics a joint venture focused on the discovery development and commercialization of microrna therapeutics founded in  alnylam maintains headquarters in cambridge massachusetts for more information please visit httpwwwalnylamcom alnylam forwardlooking statements various statements in this release concerning alnylams future expectations plans and prospects constitute forwardlooking statements for the purposes of the safe harbor provisions under the private securities litigation reform act of  actual results may differ materially from those indicated by these forwardlooking statements as a result of various important factors including the companys ability to successfully research and develop products as well as those risks more fully discussed in the risk factors section of its most recent quarterly report on form q on file with the securities and exchange commission in addition any forwardlooking statements represent alnylams views only as of today and should not be relied upon as representing its views as of any subsequent date alnylam does not assume any obligation to update any forwardlooking statements contact investors alnylam pharmaceuticals inc cynthia clayton  or media yates public relations adriana jenkins  source alnylam pharmaceuticals inc search search recent press releases  alnylam to host fourth annual rnai roundtable webcast series  alnylam and sanofi genzyme report positive results from ongoing phase  openlabel extension study with investigational rnai therapeutic fitusiran in patients with hemophilia a and b with or without inhibitors  alnylam and sanofi genzyme initiate atlas phase  program with investigational rnai therapeutic fitusiran in patients with hemophilia a and b with or without inhibitors view all releases nasdaq alny common price  change    volume  data as of  pm et on minimum  minute delay learn more alnylam appoints akshay vaishnaw as chief medical officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street alnylam appoints akshay vaishnaw as chief medical officer business wire jun    am edt alnylam pharmaceuticals inc nasdaq alny a leading rnai therapeutics company today announced that it has promoted akshay k vaishnaw md phd to the new position of chief medical officer dr vaishnaw previously held the title of senior vice president clinical research “we are delighted to promote akshay to this new role he has led the advancement of alnylam’s pipeline and has aptly earned this promotion and new recognition” said john maraganore phd chief executive officer of alnylam “alnylam is leading the development of rnai therapeutics as innovative medicines with three programs in human clinical trials currently and a total of five expected by year’s end akshay’s leadership has been instrumental in the transformation of our business from a platform company to a product company” “through the tremendous efforts of our scientists partners and collaborators the field of rnai therapeutics has seen important progress over the last year or so including the demonstration of safety and tolerability in an expanding human experience proof of rnai mechanism in man and encouraging evidence of clinical activity” said dr vaishnaw “i am excited by this progress and very much look forward to the coming months where we expect to have additional clinical data from our rnai therapeutics pipeline including alnttr for the treatment of transthyretinmediated amyloidosis alnpcs for the treatment of severe hypercholesterolemia and alnrsv for the treatment of respiratory syncytial virus i am also fortunate to work with a broader team of colleagues at alnylam who share a likeminded commitment and passion to advance rnai therapeutics as a new class of innovative medicines” dr vaishnaw joined alnylam in  he had previously been at biogen idec where he was involved in many aspects of clinical research and business development and led the effort for the approval of alefacept amevive™ for psoriasis dr vaishnaw received his md from the university of wales college of medicine uk and his phd from the university of london uk in molecular immunology he is a member of the royal college of physicians uk and received an executive mba from harvard business school in addition dr vaishnaw has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease if you liked this article you might like teslas rally has died stock falls to sixth worst performer in russell  it was the seventh best performer in the index during the first half of the year kinsey grant jul    am edt biotech movers inovio neurocrine alnylam inovio pharmaceuticals neurocrine biosciences and alnylam pharmaceuticals were among the biotech movers in premarket trading on wednesday armie margaret lee may    am edt biotech movers ionis alnylam amicus minerva ionis pharmaceuticals alnylam pharmaceuticals amicus therapeutics and minerva neurosciences were among the biotech movers in premarket trading on monday armie margaret lee may    am edt regenxbio leads biotech movers ahead of markets open also on the move were global blood therapeutics valeant and kite pharma among others alicia mcelhaney mar    am edt trending teslas model  arrives very soon  heres everything you need to know about this overhyped ride ftc seen as set to block rite aid deal when stocks fall and its not their fault cramers mad money recap friday  amazon alphabet and a gop failure on healthcare heres where wall street stands tesla is a cult stock jim cramer says advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers akshay vaishnaw alnylam pharmaceuticals inc profile  biography  bloomberg feedback akshay vaishnaw exec vpresearch  development alnylam pharmaceuticals inc career history exec vpresearch  development alnylam pharmaceuticals inc present exec vpresearch  devchief medical ofcr alnylam pharmaceuticals inc  senior vpchief medical ofcr alnylam pharmaceuticals inc  senior vpclinical research alnylam pharmaceuticals inc  vpclinical research alnylam pharmaceuticals inc  senior dirtranslational medicine biogen idec former show more website wwwalnylamcom corporate information address  rd street rd floor cambridge ma  united states phone  fax  web url wwwalnylamcom from the web personal information education md university of london phd harvard business school mba show more memberships board memberships editas medicine board member present visterra inc board member present other memberships royal college of physicians member sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data akshay vaishnaw  alnylam pharmaceuticals  email alnylamcom login  day free trial akshay vaishnaw alnylam pharmaceuticals evp rd chief medical officer export  third st cambridge ma  email format for alnylamcom direct phone not available type public employees    revenue    million industry biotechhealthcarebiotechdrugs sic code   pharmaceutical preparations biography a cambridge mabased organization alnylam pharmaceuticals is just one of the many lead profiles that you can find contact information like phone numbers and emails their profile includes alnylamcom email addresses as well as details on akshay vaishnaws email the organizations evp rd chief medical officer their profile can be found in biotechdrugs category if you also need twitter facebook linkedin wiki and biography details for akshay vaishnaw you can also find them in lead some possible email formats for akshay vaishnaw are avaishnawalnylamcom akshayvaishnawalnylamcom akshayalnylamcom and akshayvaishnawalnylamcom if you sign up for our free trial you will see our emailalnylamcom addresses similar people akshay v n  technology a android test engineer at qualcomm incorporated based in san diego ca akshay v n has a comprehensive profile on lead you can find the entry on qualcomm incorporated in our wireless category the company ceo is steve mollenkopf there are email addresses on their profile and may include akshay v n email format too you can also find other contact information like facebook phone numbers biography wiki and linkedin for akshay v n some possible email formats for akshay v n are av nqualcommcom akshayv nqualcommcom akshayqualcommcom and akshayv nqualcommcom if you sign up for our free trial you will see our emailqualcommcom addresses akshay vadher  executive akshay vadhers email address phone numbers linkedin account wiki may be included in emis healths lead profile and other emis health email addresses with the emishealthcom domain format he is part of emis health where he serves as the st line support analyst emis healths main office is set in leeds al you can check their contact information on lead under the computer hardware category some possible email formats for akshay vadher are avadheremishealthcom akshayvadheremishealthcom akshayemishealthcom and akshayvadheremishealthcom if you sign up for our free trial you will see our emailemishealthcom addresses akshay vadnere  other akshay vadnere is part of university of texas arlington an organization which has its main offices in arlington tx akshay serves as the graduate teaching assistant at university of texas arlington if youre searching for university of texas arlington email addresses you can also find those on their lead profile with the domain utaedu along with akshay vadneres linkedin name twitter tweets wiki phone numbers and biographyuniversity of texas arlingtons lead profile is categorized under the educationtraining industry some possible email formats for akshay vadnere are avadnereutaedu akshayvadnereutaedu akshayutaedu and akshayvadnereutaedu if you sign up for our free trial you will see our emailutaedu addresses similar employees barry greene  executive a cambridge mabased organization alnylam pharmaceuticals is just one of the many lead profiles that you can find contact information like phone numbers and emails their profile includes alnylamcom email addresses as well as details on barry greenes email the organizations president  their profile can be found in biotechdrugs category if you also need twitter facebook linkedin wiki and biography details for barry greene you can also find them in lead some possible email formats for barry greene are bgreenealnylamcom barrygreenealnylamcom barryalnylamcom and barrygreenealnylamcom if you sign up for our free trial you will see our emailalnylamcom addresses michael mason  other alnylam pharmaceuticalss vice president of finance  treasurer is where michael mason is employed on the other hand the organizations ceo is john maraganore they are based in cambridge ma and you can find their lead profile filed under the biotechdrugs industry michael masons profile contains twitter phone numbers linkedin wiki and contact information and you can also find other alnylam pharmaceuticals email addresses on lead with the alnylamcom domain some possible email formats for michael mason are mmasonalnylamcom michaelmasonalnylamcom michaelalnylamcom and michaelmasonalnylamcom if you sign up for our free trial you will see our emailalnylamcom addresses jeffrey cehelsky  other jeffrey cehelsky is part of alnylam pharmaceuticals an organization which has its main offices in cambridge ma jeffrey serves as the vice president clinical operations at alnylam pharmaceuticals if youre searching for alnylam pharmaceuticals email addresses you can also find those on their lead profile with the domain alnylamcom along with jeffrey cehelskys linkedin name twitter tweets wiki phone numbers and biographyalnylam pharmaceuticalss lead profile is categorized under the biotechdrugs industry some possible email formats for jeffrey cehelsky are jcehelskyalnylamcom jeffreycehelskyalnylamcom jeffreyalnylamcom and jeffreycehelskyalnylamcom if you sign up for our free trial you will see our emailalnylamcom addresses people directory  akshay vaishnaw search index english français register sign in search results if you make changes to this saved search youll find the original and new searches in your account your search filters akshay vaishnaw narrow by organization industry health care health care show top  subject directors and officers directors and officers show top  tag akshay vaishnaw earnings webcast conference call software banking show more earnings webcast conference call software banking health medical energy international biotechnology pharmaceuticals telecommunications management changes internet contracts product retail class action lawsuits electronics corporate oil manufacturing dividend entertainment real estate show top  date published past  hours past week past month custom range none between  search language english english show top  country united states united states show top  stateprovince massachusetts massachusetts show top  stock market private companies nasdaq nasdaq show top  continent show top  showing  of about  articles  editas medicine editas medicine appoints akshay vaishnaw md phd to its board of directors about  days ago  showing  of about  articles  newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved alnylam appoints akshay vaishnaw as chief medical officer  business wire alnylam appoints akshay vaishnaw as chief medical officer june    am eastern daylight time cambridge massbusiness wirealnylam pharmaceuticals inc nasdaq alny a leading rnai therapeutics company today announced that it has promoted akshay k vaishnaw md phd to the new position of chief medical officer dr vaishnaw previously held the title of senior vice president clinical research “we are delighted to promote akshay to this new role he has led the advancement of alnylam’s pipeline and has aptly earned this promotion and new recognition” said john maraganore phd chief executive officer of alnylam “alnylam is leading the development of rnai therapeutics as innovative medicines with three programs in human clinical trials currently and a total of five expected by year’s end akshay’s leadership has been instrumental in the transformation of our business from a platform company to a product company” “through the tremendous efforts of our scientists partners and collaborators the field of rnai therapeutics has seen important progress over the last year or so including the demonstration of safety and tolerability in an expanding human experience proof of rnai mechanism in man and encouraging evidence of clinical activity” said dr vaishnaw “i am excited by this progress and very much look forward to the coming months where we expect to have additional clinical data from our rnai therapeutics pipeline including alnttr for the treatment of transthyretinmediated amyloidosis alnpcs for the treatment of severe hypercholesterolemia and alnrsv for the treatment of respiratory syncytial virus i am also fortunate to work with a broader team of colleagues at alnylam who share a likeminded commitment and passion to advance rnai therapeutics as a new class of innovative medicines” dr vaishnaw joined alnylam in  he had previously been at biogen idec where he was involved in many aspects of clinical research and business development and led the effort for the approval of alefacept amevive™ for psoriasis dr vaishnaw received his md from the university of wales college of medicine uk and his phd from the university of london uk in molecular immunology he is a member of the royal college of physicians uk and received an executive mba from harvard business school in addition dr vaishnaw has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease about rna interference rnai rnai rna interference is a revolution in biology representing a breakthrough in understanding how genes are turned on and off in cells and a completely new approach to drug discovery and development its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the  nobel prize for physiology or medicine rnai is a natural process of gene silencing that occurs in organisms ranging from plants to mammals by harnessing the natural biological process of rnai occurring in our cells the creation of a major new class of medicines known as rnai therapeutics is on the horizon small interfering rnas sirnas the molecules that mediate rnai and comprise alnylam’s rnai therapeutic platform target the cause of diseases by potently silencing specific mrnas thereby preventing diseasecausing proteins from being made rnai therapeutics have the potential to treat disease and help patients in a fundamentally new way about alnylam pharmaceuticals alnylam is a biopharmaceutical company developing novel therapeutics based on rna interference or rnai the company is leading the translation of rnai as a new class of innovative medicines with a core focus on rnai therapeutics for the treatment of genetically defined diseases including alnttr for the treatment of transthyretinmediated amyloidosis attr alnpcs for the treatment of severe hypercholesterolemia and alnhpn for the treatment of refractory anemia as part of its “alnylam xtm” strategy the company expects to have five rnai therapeutic products for genetically defined diseases in advanced stages of clinical development by the end of  alnylam has additional partnerbased programs in clinical or development stages including alnrsv for the treatment of respiratory syncytial virus rsv infection alnvsp for the treatment of liver cancers and alnhtt for the treatment of huntington’s disease the company’s leadership position on rnai therapeutics and intellectual property have enabled it to form major alliances with leading companies including merck medtronic novartis biogen idec roche takeda kyowa hakko kirin and cubist in addition alnylam and isis cofounded regulus therapeutics inc a company focused on discovery development and commercialization of microrna therapeutics regulus has formed partnerships with glaxosmithkline and sanofiaventis alnylam has also formed alnylam biotherapeutics a division of the company focused on the development of rnai technologies for application in biologics manufacturing including recombinant proteins and monoclonal antibodies alnylam scientists and collaborators have published their research on rnai therapeutics in over  peerreviewed papers including many in the world’s top scientific journals such as nature nature medicine nature biotechnology and cell founded in  alnylam maintains headquarters in cambridge massachusetts for more information please visit wwwalnylamcom alnylam forwardlooking statements various statements in this release concerning alnylam’s future expectations plans and prospects including without limitation statements regarding alnylam’s expectations with respect to its “alnylam x” product strategy and the potential for rnai therapeutics including alnvsp alnttr alnpcs and alnrsv and its expectations regarding the generation and reporting of clinical data from such programs constitute forwardlooking statements for the purposes of the safe harbor provisions under the private securities litigation reform act of  actual results may differ materially from those indicated by these forwardlooking statements as a result of various important factors including without limitation alnylam’s ability to discover and develop novel drug candidates successfully demonstrate the efficacy and safety of its drug candidates including alnvsp alnttr alnpcs and alnrsv in human clinical trials and establish and maintain strategic business alliances as well as those risks more fully discussed in the “risk factors” section of its most recent quarterly report on form q on file with the securities and exchange commission in addition any forwardlooking statements represent alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date alnylam does not assume any obligation to update any forwardlooking statements contacts alnylam pharmaceuticals inccynthia clayton senior director investor relations and corporate communicationsormediaspectrumamanda sellers  x contacts alnylam pharmaceuticals inccynthia clayton senior director investor relations and corporate communicationsormediaspectrumamanda sellers  x search advanced news search advanced news search log in sign up news on akshay vaishnaw news home advertising board and executive moves energy health care hedge funds m  a private equity technology person akshay vaishnaw ▼ topic all topics ▼ organizations find news about organizations alumni find news on alumni of any org industries find news on a particular market your contacts find news on your contacts sign up for free daily alerts on this feed by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions follow change feed akshay vaishnaw alls not well at alnylam  shares dive  percent october    •  boston herald  in a statement wednesday patient safety comes first alnylam chief medical officer akshay vaishnaw also said  of the  patients died during the trial  alnylam opens new development and commercial hub in maidenhead september    •  marketline newswire  programmes in development across our three strategic therapeutic areas or stars said akshay vaishnaw executive vp of rd and chief medical officer at alnylam were  alnylam to expand global footprint with new european office in maidenhead uk september    •  business wire  programmes in development across our three strategic therapeutic areas or stars said akshay vaishnaw executive vp of rd and chief medical officer at alnylam were  editas medicine appoints akshay vaishnaw md phd to its board of directors july    •  globenewswire  nasdaqedit a leading genome editing company announced today the appointment of akshay vaishnaw md phd to its board of directors dr vaishnaw is executive vice  scholar rock announces appointment of leading fibrosis expert dr scott l friedman to scientific advisory board january    •  business wire  oregon health  sciences university and portland shriners research center and akshay vaishnaw md phd alnylam pharmaceuticals about supracellular activation scholar rock was founded on  akshay vaishnaw sold m worth of shares in alnylam pharmaceuticals inc in june  july    •  relsci data update on the move recent hires and appointments at local life science firms november    •  boston business journal  area lead for infectious diseases at vertex pharmaceuticals visterra has also named akshay vaishnaw chief medical officer of alnylam pharmaceuticals to its board raindance technologies  visterra announces additions to its management team and board of directors  veteran biotech executive josé m trevejo md phd to head clinical development and regulatory affairs industry leader akshay vaishnaw md phd frcp elected to board october    •  business wire  and is a licensed physician with board certification in infectious disease dr vaishnaw biography dr vaishnaw is currently executive vice president and chief medical officer  alnylam trumpets early promise for its sanofipartnered rnai drug october    •  fiercebiotech  even reverse disease progression with associated clinical benefit alnylam chief medical officer akshay vaishnaw said in a statement now the company is hoping to duplicate  alnylam provides early signs of effectiveness of its genefocused drugs october    •  boston business journal  stabilization of neuropathy progression after the first six months of treatment said akshay vaishnaw chief medical officer of alnylam in a statement these data will  former coo at aveo m investment come to biotech startup scholar rock september    •  boston business journal  rockefeller university and head of the blood and platelet lab there and akshay vaishnaw chief medical officer at alnylam pharmaceuticals did you find this article  scholar rock announces appointment of leading clinicians to scientific advisory board september    •  business wire  scientific advisory board barry s coller md of the rockefeller university akshay vaishnaw md phd of alnylam pharmaceuticals inc dr coller is physician in chief  akshay vaishnaw sold m worth of shares in alnylam pharmaceuticals inc in december  january    •  relsci data update related news feeds alnylam pharmaceuticals inc pharmaceuticals board and executive moves in pharmaceuticals alumni of harvard university  harvard business school email linkedin facebook google tweet reddit permalink want to see the full history of news or view news on a particular date upgrade to relsci professional now start my free trial ➤ industry select a topic keyword go  ➤ find an organization select a topic keyword go  ➤ find a person select a topic keyword go  ➤ name of a school or name of an organization select a topic keyword go  ➤ thank you you are now subscribedplease wait for the page to refresh you are now subscribed to this feed you have unsubscribed to this feed thank you you can now subscribe to more relsci news feeds to subscribe to more than one feed please enter a password please confirm your password go  ➤ youve found a premium relsci pro feature follow news on your contacts upgrade to relsci pro now to easily sync your contacts and stay in the know on the news about the people important to you start my free trial ➤ still not convinced check out our full listing of features here not now youve found a premium relsci pro feature search news on keywords curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles start my free trial ➤ still not convinced check out our full listing of features here not now industries find news on a particular market people find news about people organizations find news about organizations alumni find news on alumni of any org your contacts find news on your contacts free daily alerts sign up for free daily alerts on this feed sign up ➤ by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions already have an account click here to login are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ akshay vaishnaw  alnylam pharma insider transactions  tipranks go prologin  sign up follow✓get real time transactionsinsider detailsakshay vaishnawalnylam pharma alnyevp rd cmo not rankedakshay vaishnaws performanceakshay vaishnaw has not reported any informative transactions and therefore cannot be rankedhow are insiders ranked insider holdings  alnylam pharma alnyksee the top stocks by insiders  insider rolesalnylam pharma alny evp rd cmosee the top  corporate insiders  most profitable insider tradestock alnylam pharma alnytransaction type informative buydates nov    nov  gain see the latest stocks traded by insiders  akshay vaishnaws trading historybased on form  follow✓get real time transactionscompany nameinsider positionholding valuelast transactionlast transaction amountlast transaction datealnyalnylam pharmaevp rd cmouninformative buyjun  editeditas medicine incdirectorsee all insider trading from today you may also likemeet our smart portfolio see what top analysts say about your stocksget a breakdown of the different strategies based on detected insider trading activityfind the best performing analyst in each sector follow them so you never miss a recommendationrelated linkshow can i benefit from insider trading see the top  corporate insiders go to hot stocks by insiders find which stocks insiders traded today become a tipranks memberget the best investing tips  hacks straight to your emailfree membershipsubmitinsider trading daily newsletterprofessional daytrading strategy based on predictive insider transactionsannual return learn more powered by akshay vaishnaw evp chief medical officer alnylam pharmaceuticals timesjavascript is disabled market profiles login sign up login sign up   edit person akshay vaishnaw evp chief medical officer at alnylam pharmaceuticals location boston ma add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop akshay vaishnaw evp chief medical officer at alnylam pharmaceuticals location boston ma add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop dr vaishnaw is currently executive vice president and chief medical officer of alnylam pharmaceuticals inc which he joined in  under his leadership at alnylam the company is developing a novel class of medicines rnai therapeutics from which seven distinct programs have entered clinical trials previously dr vaishnaw was senior director translational medicine at biogen inc now biogen idec inc where he was involved in many aspects of clinical research and business development and led the effort for the approval of alefacept amevive™ for psoriasis dr vaishnaw received his md from the university of wales college of medicine uk with distinctions in pathology and medicine and his phd from the university of london uk in molecular immunology he is a fellow of the royal college of physicians uk  companies in career na related markets na colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags clinical research medical research medicine topics of influence web site na careers achievements investments related people edit view all akshay vaishnawcareer   visterra board member jul alnylam pharmaceuticals evp chief medical officer jul to jun alnylam pharmaceuticals svp chief medical officer competencies edit view all akshay vaishnaweducation   royal college of physicians uk frcp internal medicine  harvard business school program for management development  cornell university medical center rheumatology fellow sle foundation fellow rheumatology mechanisms of autoimmunity  university of london uk immunology  royal college of physicians uk mrcp internal medicine  university of wales college of medicine cardiff uk medicine edit akshay vaishnawachievements and recognitions add milestone no milestones has been recorded for akshay vaishnaw edit akshay vaishnawlinks add link no links has been recorded for akshay vaishnaw akshay vaishnawinvestmentsacquisitions no investments has been recorded for akshay vaishnaw akshay vaishnawinvestments representing others no investment reps has been recorded for akshay vaishnaw akshay vaishnawrelated people no colleagues and peers has been recorded for akshay vaishnaw view all akshay vaishnawrecommended market profiles  telemedicine  or more employees  companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees  companies shared economy landscape jeremiah owyang  or more employees  companies inside sales landscape  or more employees  companies